HC Wainwright & Co. Maintains Buy on Iovance Biotherapeutics, Raises Price Target to $20

Benzinga · 1d ago
HC Wainwright & Co. analyst Joseph Pantginis maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and raises the price target from $9 to $20.